Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. At 12 ...
The antiplatelet agent clopidogrel has been shown to reduce the postoperative risk of stroke, myocardial infarction (MI) and death in patients with non-ST-segment elevation acute coronary syndromes ...
Background A 67-year-old man with supraventricular tachycardia associated with angina underwent coronary angiographic assessment. This investigation revealed mild coronary artery disease in his left ...
Current evidence seems to indicate that due to individual variability in response to clopidogrel, as many as 30% of patients on maintenance clopidogrel (75 mg/day) may show elevated platelet ...
PARIS, France—Older patients with non-ST-elevation acute coronary syndrome treated with ticagrelor (Brilinta; AstraZeneca) are at a significantly increased risk of bleeding when compared with patients ...
The effect of single as compared with dual antiplatelet treatment on bleeding and thromboembolic events after transcatheter aortic-valve implantation (TAVI) in patients who do not have an indication ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback